Platelet function monitoring in patients on clopidogrel

Interventional Medicine and Applied Science

Volumn 3, Issue 1, 2011, Pages 32-38

  Aradi, Dániel ^a   Rideg, Orsolya ^a   Komócsi, András ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

clopidogrel; PCI; platelet function testing

Indexed keywords

EID: 84858292416     PISSN: 20611617     EISSN: 20615094     Source Type: Journal    
DOI: 10.1556/IMAS.3.2011.1.7     Document Type: Review

References (38)

1. Patrono C, Bachmann F, Baigent C et al.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25, 166-181 (2004)
2. Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 357, 2482-2494 (2007)
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308, 81-106 (1994)
4. Leon MB, Baim DS, Popma JJ et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 339, 1665-1671 (1998)
5. Urban P, Macaya C, Rupprecht HJ et al.: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98, 2126-2132 (1998)
6. Komocsi A, Vorobcsuk A, Aradi D: Transradial percutaneous coronary intervention in acute myocardial infarction. Interv Med Appl Sci 2, 53-58 (2010)
7. Berger PB: Results of the ticlid or plavix post-stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr Control Trials Cardiovasc Med 1, 83-87 (2000)
8. Bhatt DL, Bertrand ME, Berger PB et al.: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39, 9-14 (2002)
9. Steinhubl SR, Berger PB, Mann JT III et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002)
10. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001)
11. Chen ZM, Jiang LX, Chen YP et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005)
12. Jaremo P, Lindahl TL, Fransson SG, Richter A: Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252, 233-238 (2002)
13. Barragan P, Bouvier JL, Roquebert PO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59, 295-302 (2003)
14. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004)
15. Bonello L, Tantry US, Marcucci R et al.: Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56, 919-933 (2010)
16. Aradi D, Horvath I, Konyi A et al.: Efficacy of thienopyridine therapy influences late outcome after coronary stent implantation. Am J Cardiol 98, 202M-202M (2006)
17. Serebruany VL, Steinhubl SR, Berger PB et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45, 246-251 (2005)
18. Verstuyft C, Simon T, Kim RB: Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J 30, 1943-1963 (2009)
19. Serebruany V, Cherala G, Williams C et al.: Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". Am Heart J 158, 925-932 (2009)
20. Bernlochner I, Steinhubl S, Braun S et al.: Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 104, 1193-1200 (2010)
21. Mega JL, Close SL, Wiviott SD et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312-1319 (2010)
22. Hochholzer W, Trenk D, Fromm MF et al.: Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55, 2427-2434 (2010)
23. Shuldiner AR, O'Connell JR, Bliden KP et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009)
24. *3 alleles are associated with stent thrombosis: a casecontrol study. Eur Heart J 31, 3046-3053 (2010)
25. Breet NJ, Van Werkum JW, Bouman HJ et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010)
26. Aradi D, Komocsi A, Vorobcsuk A et al.: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160, 543-551 (2010)
27. Gurbel PA, Tantry US: Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv 3, 1008-1010 (2010)
28. Wijns W, Kolh P, Danchin N et al.: Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 31, 2501-2555 (2010)
29. Silber S, Albertsson P, Aviles FF et al.: Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26, 804-847 (2005)
30. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.: ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary interventionsummary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47, 216-235 (2006)
31. Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51, 1404-1411 (2008)
32. Aradi D, Vorobcsuk A, Lenkey Z, Horvath IG, Komocsi A.: Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 21, 1-10 (2010)
33. Gurbel PA, Bliden KP, Butler K et al.: Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121, 1188-1199 (2010)
34. Angiolillo DJ, Saucedo JF, Deraad R et al.: Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56, 1017-1023 (2010)
35. Aradi D, Vorobcsuk A, Pinter T et al.: Doubling the maintenance dose of clopidogrel in patients with high post-clopidogrel platelet reactivity after percutaneous coronary intervention: the DOSER randomized, placebo-controlled trial. Eur Heart J 31, 970-970 (2010)
36. Ari H, Ozkan H, Karacinar A et al.: The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol (2011)
37. Price MJ: Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. Circulation 122, 2218-2218 (2010)
38. Szél Á, Merkely B, Hüttl K et al.: Statement on ethical publishing and scientific authorship. Interv Med Appl Sci 2, 101-102 (2010)